NCT03162562View on ClinicalTrials.gov

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

November 5, 2020

Study Completion Date

November 5, 2020

Conditions
Cancer of OvaryNeoplasms, OvarianOvarian Cancer Stage IVOvarian Cancer RecurrentOvarian Cancer Stage IIIOvary Cancer
Interventions
BIOLOGICAL

Oregovomab

Monoclonal antibody against CA 125

DRUG

Poly ICLC

Immune adjuvant

Trial Locations (2)

23298

VCU Massey Cancer Center, Dalton Oncology Clinic, Richmond

32804

Florida Hospital Cancer Institute, Orlando

Sponsors

Lead Sponsor

CanariaBio Inc.
All Listed Sponsors
lead

CanariaBio Inc.

INDUSTRY

NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter